vs

Side-by-side financial comparison of Pediatrix Medical Group, Inc. (MD) and MILLERKNOLL, INC. (MLKN). Click either name above to swap in a different company.

MILLERKNOLL, INC. is the larger business by last-quarter revenue ($955.2M vs $493.8M, roughly 1.9× Pediatrix Medical Group, Inc.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs 2.5%, a 4.3% gap on every dollar of revenue. On growth, MILLERKNOLL, INC. posted the faster year-over-year revenue change (-1.6% vs -1.7%).

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

MillerKnoll, Incorporated, doing business as Herman Miller, is an American company that produces office furniture, equipment, and home furnishings. Its best known designs include the Aeron chair, Noguchi table, Marshmallow sofa, Mirra chair, and Eames Lounge Chair. Herman Miller is also credited with the 1968 invention of the office cubicle under then–director of research Robert Propst.

MD vs MLKN — Head-to-Head

Bigger by revenue
MLKN
MLKN
1.9× larger
MLKN
$955.2M
$493.8M
MD
Growing faster (revenue YoY)
MLKN
MLKN
+0.1% gap
MLKN
-1.6%
-1.7%
MD
Higher net margin
MD
MD
4.3% more per $
MD
6.8%
2.5%
MLKN

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
MD
MD
MLKN
MLKN
Revenue
$493.8M
$955.2M
Net Profit
$33.7M
$24.2M
Gross Margin
39.0%
Operating Margin
9.9%
5.1%
Net Margin
6.8%
2.5%
Revenue YoY
-1.7%
-1.6%
Net Profit YoY
10.5%
-29.0%
EPS (diluted)
$0.40
$0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MD
MD
MLKN
MLKN
Q4 25
$493.8M
$955.2M
Q3 25
$492.9M
$955.7M
Q2 25
$468.8M
Q1 25
$458.4M
Q4 24
$502.4M
Q3 24
$511.2M
Q2 24
$504.3M
Q1 24
$495.1M
Net Profit
MD
MD
MLKN
MLKN
Q4 25
$33.7M
$24.2M
Q3 25
$71.7M
$20.2M
Q2 25
$39.3M
Q1 25
$20.7M
Q4 24
$30.5M
Q3 24
$19.4M
Q2 24
$-153.0M
Q1 24
$4.0M
Gross Margin
MD
MD
MLKN
MLKN
Q4 25
39.0%
Q3 25
38.5%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
MD
MD
MLKN
MLKN
Q4 25
9.9%
5.1%
Q3 25
13.8%
5.6%
Q2 25
12.8%
Q1 25
7.0%
Q4 24
7.8%
Q3 24
6.6%
Q2 24
-31.3%
Q1 24
3.2%
Net Margin
MD
MD
MLKN
MLKN
Q4 25
6.8%
2.5%
Q3 25
14.5%
2.1%
Q2 25
8.4%
Q1 25
4.5%
Q4 24
6.1%
Q3 24
3.8%
Q2 24
-30.3%
Q1 24
0.8%
EPS (diluted)
MD
MD
MLKN
MLKN
Q4 25
$0.40
$0.35
Q3 25
$0.84
$0.29
Q2 25
$0.46
Q1 25
$0.24
Q4 24
$0.37
Q3 24
$0.23
Q2 24
$-1.84
Q1 24
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MD
MD
MLKN
MLKN
Cash + ST InvestmentsLiquidity on hand
$375.2M
$180.4M
Total DebtLower is stronger
$570.5M
$1.3B
Stockholders' EquityBook value
$865.9M
$1.3B
Total Assets
$2.2B
$3.9B
Debt / EquityLower = less leverage
0.66×
1.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MD
MD
MLKN
MLKN
Q4 25
$375.2M
$180.4M
Q3 25
$340.1M
$167.2M
Q2 25
$224.7M
Q1 25
$99.0M
Q4 24
$229.9M
Q3 24
$103.8M
Q2 24
$19.4M
Q1 24
$8.0M
Total Debt
MD
MD
MLKN
MLKN
Q4 25
$570.5M
$1.3B
Q3 25
$577.2M
$1.3B
Q2 25
$583.9M
Q1 25
$590.5M
Q4 24
$597.1M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
MD
MD
MLKN
MLKN
Q4 25
$865.9M
$1.3B
Q3 25
$890.7M
$1.3B
Q2 25
$833.8M
Q1 25
$789.2M
Q4 24
$764.9M
Q3 24
$732.5M
Q2 24
$706.5M
Q1 24
$856.2M
Total Assets
MD
MD
MLKN
MLKN
Q4 25
$2.2B
$3.9B
Q3 25
$2.2B
$3.9B
Q2 25
$2.1B
Q1 25
$2.0B
Q4 24
$2.2B
Q3 24
$2.1B
Q2 24
$2.0B
Q1 24
$2.2B
Debt / Equity
MD
MD
MLKN
MLKN
Q4 25
0.66×
1.02×
Q3 25
0.65×
1.02×
Q2 25
0.70×
Q1 25
0.75×
Q4 24
0.78×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MD
MD
MLKN
MLKN
Operating Cash FlowLast quarter
$114.1M
$64.6M
Free Cash FlowOCF − Capex
$34.0M
FCF MarginFCF / Revenue
3.6%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
3.39×
2.67×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MD
MD
MLKN
MLKN
Q4 25
$114.1M
$64.6M
Q3 25
$137.3M
$9.4M
Q2 25
$137.2M
Q1 25
$-117.5M
Q4 24
$133.0M
Q3 24
$91.8M
Q2 24
$107.0M
Q1 24
$-125.2M
Free Cash Flow
MD
MD
MLKN
MLKN
Q4 25
$34.0M
Q3 25
$-21.3M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
MD
MD
MLKN
MLKN
Q4 25
3.6%
Q3 25
-2.2%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
MD
MD
MLKN
MLKN
Q4 25
3.2%
Q3 25
3.2%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
MD
MD
MLKN
MLKN
Q4 25
3.39×
2.67×
Q3 25
1.91×
0.47×
Q2 25
3.49×
Q1 25
-5.66×
Q4 24
4.36×
Q3 24
4.72×
Q2 24
Q1 24
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

MLKN
MLKN

Workplace$309.9M32%
Global Retail Segment$275.8M29%
International Contract Segment$170.9M18%
Performance Seating$101.1M11%
Lifestyle$52.9M6%
Other Products$44.6M5%

Related Comparisons